Regeneron Pharmaceuticals (DE:RGO)
NASDAQ:RGO
RGO Stock Chart & Stats
€648.40
-€7.80(-1.10%)
At close: 4:00 PM EST
€648.40
-€7.80(-1.10%)
Day’s Range― - ―
52-Week Range€420.00 - €702.60
Previous CloseN/A
Volume0.00
Average Volume (3M)44.00
Market Cap
€67.79B
Enterprise Value€76.24B
Total Cash (Recent Filing)€8.61B
Total Debt (Recent Filing)€2.71B
Price to Earnings (P/E)17.9
Beta0.32
Next Earnings
Apr 29, 2026EPS Estimate
7.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.95
Shares Outstanding103,902,660
10 Day Avg. Volume59
30 Day Avg. Volume44
Financial Highlights & Ratios
PEG Ratio3.38
Price to Book (P/B)2.58
Price to Sales (P/S)5.63
P/FCF Ratio19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€759.99Price Target Upside17.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)39.3
Revenue Forecast (FY)€13.60B
Bulls Say, Bears Say
Bulls Say
Clinical Trial UpsideEncouraging early clinical data showing durable progression-free survival support a favorable probability that a positive randomized trial for the fianlimab plus Libtayo combination could materially expand first-line melanoma market share and create significant commercial upside.
Established Product ResilienceDupixent's long safety record together with ongoing label-expansion efforts functions like an internal pipeline, supporting sustained sales growth and creating a competitive barrier that is difficult for new entrants to overcome.
Pipeline And Commercialization PotentialA diversified late-stage pipeline, including an obesity candidate with competitive phase results and plans to co-formulate that agent with an established cholesterol therapy, could broaden revenue streams and drive future commercial growth.
Bears Say
Competitive Positioning RiskBeing several years behind the leading competitor means the fianlimab combination must show clear superiority in a head-to-head setting to persuade physicians to switch, otherwise uptake could remain limited.
Franchise Pressure And Margin ImpactThe eye-care franchise faces sales pressure from dose mix shifts and biosimilar entrants, while guidance pointing to lower gross margins from product mix and investments could weigh on near-term profitability and revenue momentum.
Late‑stage Trial RiskPromising early‑stage efficacy signals may not hold up in larger randomized trials, and adjuvant and lung cancer programs face specific biological and design challenges that reduce the probability of success in those indications.
Regeneron News
RGO FAQ
What was Regeneron Pharmaceuticals’s price range in the past 12 months?
Regeneron Pharmaceuticals lowest stock price was €420.00 and its highest was €702.60 in the past 12 months.
What is Regeneron Pharmaceuticals’s market cap?
Regeneron Pharmaceuticals’s market cap is €67.79B.
When is Regeneron Pharmaceuticals’s upcoming earnings report date?
Regeneron Pharmaceuticals’s upcoming earnings report date is Apr 29, 2026 which is in 30 days.
How were Regeneron Pharmaceuticals’s earnings last quarter?
Regeneron Pharmaceuticals released its earnings results on Jan 30, 2026. The company reported €9.945 earnings per share for the quarter, beating the consensus estimate of €9.333 by €0.612.
Is Regeneron Pharmaceuticals overvalued?
According to Wall Street analysts Regeneron Pharmaceuticals’s price is currently Undervalued.
Does Regeneron Pharmaceuticals pay dividends?
Regeneron Pharmaceuticals does not currently pay dividends.
What is Regeneron Pharmaceuticals’s EPS estimate?
Regeneron Pharmaceuticals’s EPS estimate is 7.91.
How many shares outstanding does Regeneron Pharmaceuticals have?
Regeneron Pharmaceuticals has 103,902,660 shares outstanding.
What happened to Regeneron Pharmaceuticals’s price movement after its last earnings report?
Regeneron Pharmaceuticals reported an EPS of €9.945 in its last earnings report, beating expectations of €9.333. Following the earnings report the stock price went down -0.865%.
Which hedge fund is a major shareholder of Regeneron Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:RGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€759.99 (17.21% Upside)
€759.99 (17.21% Upside)
Blogger Sentiment
Bullish
DE:RGO Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.65%
12-Months-Change
Fundamentals
Return on Equity
14.83%
Trailing 12-Months
Asset Growth
7.15%
Trailing 12-Months
Company Description
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
RGO Company Deck
RGO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial strength (notably Dupixent, EYLEA HD, Libtayo), solid financials, strong cash generation, aggressive shareholder returns, and a deep pipeline with multiple near‑term readouts and regulatory objectives. Headwinds were acknowledged — including EYLEA 2 mg biosimilar pressure, short‑term inventory timing, manufacturing/regulatory risk for the prefilled syringe, patient affordability challenges, and higher R&D and SG&A investments. On balance, the positives — large, high‑growth franchises, robust cash flow, and multiple potentially transformative clinical programs — materially outweigh the near‑term challenges and risks discussed.View all DE:RGO earnings summariesRGO Revenue Breakdown
43.99% Net product sales
51.11% Collaboration revenue
4.90% Other revenue
RGO Stock 12 Month Forecast
Average Price Target
€759.99
▲(17.21% Upside)
Technical Analysis
Options Prices
Currently, No data available
---